Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2021

View Archived Issues

Discovery and preclinical characterization of a novel anti-SARS-CoV-2 MAb, MW-06

Heparegenix identifies new MAPKK 4 inhibitors

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent PROTACs targeting cereblon

Dongguan Hec New Drug Research and Development, Sunshine Lake Pharma identify HBV inhibitors

New SHP-2 inhibitors identified at Beijing Innocare Pharmaceutical Technology

ImmVira receives NMPA approval for clinical testing of intravenous MVR-T3011

Ichnos nominates ISB-1442 as its next clinical candidate

Targeting synaptogyrin-3 can ameliorate cognitive deficits

AIkido to use machine learning in development of novel broad-spectrum antivirals

Initial results presented from first-in-human study of ABNCoV2 vaccine

Bentrio shows prophylactic and therapeutic effects against influenza A

Proteins found to promote neuroinflammation in MS

Phase II study of ASC-40 for the treatment of acne vulgaris approved in China

Antengene and MindRank AI collaborate to advance difficult-to-drug molecular targets

Enrollment ongoing in phase II study of USB-002 for respiratory distress due to COVID-19

Signal peptide peptidase-like 2B has a pathogenic role in Alzheimer's disease

Atridia initiates phase I study of SHR-1905

Initiation of phase I/II clinical trial of AK-117 in patients with AML

AstraZeneca starts phase II SOLANO study of AZD-8233

Response rate shows potential of ficlatuzumab with chemotherapy in treating AML

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...